OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma (NASDAQ: OKYO) announced on October 16, 2025 that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 ordinary shares on NASDAQ. The purchase increases the chairman's total holding to 10,382,677 shares. The company is developing urcosimod for neuropathic corneal pain, a condition currently without an FDA-approved therapy.
OKYO Pharma (NASDAQ: OKYO) ha annunciato il 16 ottobre 2025 che Panetta Partners Limited, una società in cui l'Amministratore Delegato Esecutivo Gabriele Cerrone possiede un interesse economico, ha acquistato 210.000 azioni ordinarie sul NASDAQ. L'acquisto aumenta la partecipazione totale del presidente a 10.382.677 azioni. L'azienda sta sviluppando urcosimod per il dolore neuropatico della superficie oculare, una condizione al momento priva di una terapia approvata dalla FDA.
OKYO Pharma (NASDAQ: OKYO) anunció el 16 de octubre de 2025 que Panetta Partners Limited, una entidad en la que el PRESIDENTE EJECUTIVO Gabriele Cerrone tiene un interés beneficioso, procedió a adquirir 210.000 acciones ordinarias en NASDAQ. La compra eleva la participación total del presidente a 10.382.677 acciones. La compañía está desarrollando urcosimod para el dolor neuropático de la córnea, una condición para la cual actualmente no existe una terapia aprobada por la FDA.
OKYO Pharma (NASDAQ: OKYO)는 2025년 10월 16일에 Executive Chairman Gabriele Cerrone가 유익한 이해 관계를 가진 기관인 Panetta Partners Limited가 210,000주 보통주를 NASDAQ에서 매입했다고 발표했습니다. 이번 매매로 회장의 총 보유 주식 수는 10,382,677주로 증가합니다. 이 회사는 FDA 승인을 받지 못한 urcosimod를 개발 중입니다.
OKYO Pharma (NASDAQ: OKYO) a annoncé le 16 octobre 2025 que Panetta Partners Limited, une entité dans laquelle le Président Exécutif Gabriele Cerrone détient un intérêt bénéficiaire, a acquis 210 000 actions ordinaires sur le NASDAQ. L'achat porte la participation totale du président à 10 382 677 actions. L'entreprise développe urcosimod pour la douleur neuropathique de la cornée, une condition pour laquelle il n'existe actuellement aucun traitement approuvé par la FDA.
OKYO Pharma (NASDAQ: OKYO) gab am 16. Oktober 2025 bekannt, dass Panetta Partners Limited, eine Gesellschaft, an der der Executive Chairman Gabriele Cerrone eine wirtschaftliche Beteiligung hat, 210.000 Stammaktien an der NASDAQ erworben hat. Der Kauf erhöht die Gesamtbeteiligung des Vorsitzenden auf 10.382.677 Aktien. Das Unternehmen entwickelt urcosimod zur neuropathischen Hornhautschmerz, einer Erkrankung, für die es derzeit keine von der FDA genehmigte Therapie gibt.
OKYO Pharma (NASDAQ: OKYO) أعلنت في 16 أكتوبر 2025 أن Panetta Partners Limited، وهي كيان يمتلك الرئيس التنفيذي المشارك غابرييل سيروني مصلحة فيه، قامت بشراء 210,000 سهماً عادياً في NASDAQ. هذا الشراء يجعل حصة الرئيس الإجمالية تبلغ 10,382,677 سهماً. الشركة تطور urcosimod لعلاج ألم القرنية العصبي، وهي حالة لا توجد لها حالياً علاج معتمد من Food and Drug Administration (FDA).
OKYO Pharma (NASDAQ: OKYO) 于 2025年10月16日宣布，执行董事长 Gabriele Cerrone 所持有利益的 Panetta Partners Limited 实体已在 NASDAQ 收购了 210,000 股普通股。此次交易使董事长的总持股增至 10,382,677 股。公司正在开发 urcosimod 用于神经性角膜疼痛，这是一种目前尚无 FDA 批准治疗方案的病症。
- Insider purchase of 210,000 shares on Oct 16, 2025
- Executive Chairman's total stake is 10,382,677 shares
- Purchase price not disclosed in the announcement
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 210,000 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,382,677 shares.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.
For further information, please visit www.okyopharma.com.
Inquiries:
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
What shares did Gabriele Cerrone acquire in OKYO on October 16, 2025?
How many total OKYO shares does the Executive Chairman hold after the October 16, 2025 purchase?
Does the OKYO release state the purchase price for the 210,000 shares?
What program is OKYO developing and does it have FDA-approved therapy?
Could the chairman's share purchase affect OKYO shareholder sentiment?
